Full Professor, Faculty of medicine, Laval University
Director of the Canadian research Chair in translational research in pulmonary vascular diseases
Pulmonary Hypertension Research Group
Centre de recherche de lâ€™Institut universitaire de cardiologie et pneumologie de QuĂ©bec (CRIUCPQ)
2725, chemin Sainte-Foy, QuĂ©bec (QuĂ©bec), Canada, G1V 4G5
After having completed a doctorate degree in vascular physiopathology in France and a post-doctorate degree in vascular biology in Alberta, Dr. Bonnet settled in QuĂ©bec city, as an associate professor at UniversitĂ© Laval and a researcher at the Research Centre of the IUCPQ where he continues his research in the cardiovascular field. Professor Bonnet was named Fellow of American Heart Association and Director of the Canadian Research Chair in vascular pathology. This title, considered as one of the greatest honors in the scientific community, is allotted to researchers who showed leadership, creativity and exceptional competence in the advancement of fundamental and clinical research in the cardiovascular field. The accomplishments of Professor Bonnet led to the discovery of mechanisms causing pulmonary arterial hypertension, a fatal disease which strikes mainly young adults. His team also discovered two substances likely to treat this disease effectively. Drs Bonnet and Provencher are the founders and directors of the pulmonary hypertension research group.
Pulmonary arterial hypertension (PAH); chronic obstructive pulmonary disease (COPD); coronary disease.
The group of Dr. Bonnet uses a multidisciplinary and translational approach (from genes to population) in order to study the molecular and cellular mechanisms involved in the development of the process of vascular and bronchial remodeling. This work allows the identification of new biomarkers, thus improving the identification and clinical management of individuals afflicted by PAH. His research also identified new therapeutic targets such as Pim-1, miR-204 or PARP-1 in PAH. In addition, numerous works carried out in the laboratory of Dr. Bonnet aim at evaluating the impact of these targets in the COPD and the coronary diseases which have several similarities with PAH. The recent association of Drs Bonnet and Provencher creating the pulmonary hypertension research group offers new prospects of research in PAH. Indeed, the association of the fundamental research of Dr. Bonnet to the clinical research of Dr. Provencher allows research projects initiated in the laboratory to reach the patient's bedside which will accelerate, without any doubt, the discovery of new therapies.
Click here to see Dr Bonnet's publications